# G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer

> **NCT03455270** · PHASE1 · COMPLETED · sponsor: **G1 Therapeutics, Inc.** · enrollment: 107 (actual)

## Conditions studied

- Carcinoma, Ductal, Breast
- Breast Cancer Female
- Breast Neoplasm
- Breast Cancer
- Metastatic Breast Cancer
- Advanced Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **DRUG:** G1T48
- **DRUG:** Palbociclib

## Key facts

- **NCT ID:** NCT03455270
- **Lead sponsor:** G1 Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-09
- **Primary completion:** 2022-09-29
- **Final completion:** 2022-09-29
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2022-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03455270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03455270, "G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03455270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*